Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | F7 | P08709 | 1/20 | 0.46 |
| ▸ | F3 | P13726 | 1/20 | 0.46 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.46 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.46 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | PLOD2 | O00469 | 2/20 | 0.41 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.41 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6062256 | 0.80 | KDM4E (0.43) | ALDH1A1HCAR2HDAC1HDAC6CYP3A4 | |
| SCHEMBL8060987 | 0.76 | ALDH1A1 (0.49) | ALDH1A1APPGAAHCAR3HCAR2 | |
| SCHEMBL7619693 | 0.76 | ALDH1A1 (0.49) | ALDH1A1APPGAAHCAR3HCAR2 | |
| SCHEMBL1242243 | 0.75 | ALDH1A1 (0.71) | ALDH1A1APPGAAHCAR3HCAR2 | |
| SCHEMBL29915528 | 0.75 | ALDH1A1 (0.71) | ALDH1A1APPGAAHCAR3HCAR2 | |
| SCHEMBL14324877 | 0.75 | SIRT2 (0.59) | ALDH1A1APPGAAHCAR3HCAR2 | |
| SCHEMBL10493916 | 0.75 | F7 (0.50) | ALDH1A1APPGAAHCAR3HCAR2 | |
| SCHEMBL5791591 | 0.74 | KDM4E (0.57) | ALDH1A1GAALMNAL3MBTL1CYP1A2 | |
| SCHEMBL3409177 | 0.74 | ALDH1A1 (0.50) | ALDH1A1APPGAAHCAR3HCAR2 | |
| SCHEMBL3407076 | 0.74 | PRKCI (0.57) | ALDH1A1APPGAAHCAR3HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9597327-B2 | Synthesis of (R)-N-methylnaltrexone | PROGENICS PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150290187-A1 | SYNTHESIS OF (R)-N-METHYLNALTREXONE | Progenics Pharmaceuticals., Inc. | 2015-10-15 | — | — | US | disclosed |
| US-8343992-B2 | Synthesis of R-N-methylnaltrexone | PROGENICS PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100311781-A1 | SYNTHESIS OF R-N-METHYLNALTREXONE | PROGENICS PHARMACEUTICALS, INC. | 2010-12-09 | — | — | US | disclosed |
| US-6440933-B1 | PEPTIDE DERIVATIVES WHICH ARE DIHYDROPYRIDINE-PYRIDINIUM SALT-TYPE REDOX TARGETOR MOIETY, A BULKY LIPOPHILIC FUNCTION AND AN AMINO ACID/DIPEPTIDE/TRIPEPTIDE SPACER; GROWTH FACTOR INHIBITOR, ESPECIALLY SOMATOSTATIN ANALOGS, RETINA | UNIVERSITY OF FLORIDA | 2002-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311781-A1 | SYNTHESIS OF R-N-METHYLNALTREXONE | OPRM1, OPRK1, OPRL1 | ALDH1A1 2513/4885APP 3823/4885GAA 4026/4885 |
| US-20150290187-A1 | SYNTHESIS OF (R)-N-METHYLNALTREXONE | OPRM1, OPRL1, OPRK1 | ALDH1A1 2659/4885APP 3761/4885GAA 3461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.